The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis
Open accessAbstract
Cisplatin is a chemotherapeutic drug commonly used in clinics. However, acquired resistance confines its application in chemotherapeutics. To overcome the acquired resistance to cisplatin, it is reasoned, based on our previous findings of mediation of cellular responses by [Gd@C 82(OH)22]n nanoparticles, that [Gd@C 82(OH)22]n may reverse tumor resistance to cisplatin by reactivating the impaired endocytosis of cisplatin-resistant human prostate cancer (CP-r) cells. Here we report that exposure of the CP-r PC-3-luc cells to cisplatin in the presence of nontoxic [Gd@C 82(OH)22]n not only decreased the number of surviving CP-r cells but also inhibited growth of the CP-r tumors in athymic nude mice as measured by both optical and MRI. Labeling the CP-r PC-3 cells with transferrin, an endocytotic marker, demonstrated that pretreatment of the CP-r PC-3-luc cells with [Gd@C 82(OH)22]n enhanced intracellular accumulation of cisplatin and formation of cisplatin-DNA adducts by restoring the defective endocytosis of the CP-r cancer cells. The results suggest that [Gd@C 82(OH)22]n nanoparticles overcome tumor resistance to cisplatin by increasing its intracellular accumulation through the mechanism of restoring defective endocytosis. The technology can be extended to other challenges related to multidrug resistance often found in cancer treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kroto, H. W., Heath, J. R., O’Brien, S. C., Curl, R. F., & Smalley, R. E. (1985) · Nature · doi:10.1038/318162a0 · Cited by 16,083
Solid C60: a new form of carbon
Krätschmer, W., Lamb, L. D., Fostiropoulos, K., & Huffman, D. R. (1990) · Nature · doi:10.1038/347354a0 · Cited by 7,646
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Nanoparticle-mediated cellular response is size-dependent
Jiang, W., Kim, B. Y. S., Rutka, J. T., & Chan, W. C. W. (2008) · Nature Nanotechnology · doi:10.1038/nnano.2008.30 · Cited by 2,776
Dhar, S., Gu, F. X., Langer, R., Farokhzad, O. C., & Lippard, S. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809154105 · Cited by 994
Cell Surface P-Glycoprotein Associated with Multidrug Resistance in Mammalian Cell Lines
Kartner, N., Riordan, J. R., & Ling, V. (1983) · Science · doi:10.1126/science.6137059 · Cited by 991
Cellular accumulation of the anticancer agent cisplatin: A review
Gately, D., & Howell, S. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.221 · Cited by 572
Safaei, R., Larson, B. J., Cheng, T. C., Gibson, M. A., Otani, S., Naerdemann, W., & Howell, S. B. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0102 · Cited by 564
The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based Chemotherapy
Hall, M. D., Okabe, M., Shen, D.-W., Liang, X.-J., & Gottesman, M. M. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.080907.180426 · Cited by 474
Self-citationParamagnetic Water-Soluble Metallofullerenes Having the Highest Relaxivity for MRI Contrast Agents
Mikawa, M., Kato, H., Okumura, M., Narazaki, M., Kanazawa, Y., Miwa, N., & Shinohara, H. (2001) · Bioconjugate Chemistry · doi:10.1021/bc000136m · Cited by 462
Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis
Murphy, E. A., Majeti, B. K., Barnes, L. A., Makale, M., Weis, S. M., Lutu-Fuga, K., Wrasidlo, W., & Cheresh, D. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803728105 · Cited by 455
Yin, J.-J., Lao, F., Fu, P. P., Wamer, W. G., Zhao, Y., Wang, P. C., Qiu, Y., Sun, B., Xing, G., Dong, J., et al. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2008.09.061 · Cited by 448
Self-citationBolskar, R. D., Benedetto, A. F., Husebo, L. O., Price, R. E., Jackson, E. F., Wallace, S., Wilson, L. J., & Alford, J. M. (2003) · Journal of the American Chemical Society · doi:10.1021/ja0340984 · Cited by 400
Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance.
Andrews, P. A., & Howell, S. B. (1990) · PubMed · Cited by 397
Chen, C., Xing, G., Wang, J., Zhao, Y., Li, B., Tang, J., Jia, G., Wang, T., Sun, J., Xing, L., et al. (2005) · Nano Letters · doi:10.1021/nl051624b · Cited by 298
Self-citationPreclinical Perspectives on Platinum Resistance
Kelland, L. R. (2000) · Drugs · doi:10.2165/00003495-200059004-00001 · Cited by 280
Lanthanoid Endohedral Metallofullerenols for MRI Contrast Agents
Kato, H., Kanazawa, Y., Okumura, M., Taninaka, A., Yokawa, T., & Shinohara, H. (2003) · Journal of the American Chemical Society · doi:10.1021/ja027555+ · Cited by 261
Photodynamic Effect of Polyethylene Glycol–modified Fullerene on Tumor
Tabata, Y., Murakami, Y., & Ikada, Y. (1997) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1997.tb00336.x · Cited by 212
How do real tumors become resistant to cisplatin?
Borst, P., Rottenberg, S., & Jonkers, J. (2008) · Cell Cycle · doi:10.4161/cc.7.10.5930 · Cited by 192
The Role of the Mammalian Copper Transporter 1 in the Cellular Accumulation of Platinum-Based Drugs
Larson, C. A., Blair, B. G., Safaei, R., & Howell, S. B. (2009) · Molecular Pharmacology · doi:10.1124/mol.108.052381 · Cited by 182
Antioxidative function and biodistribution of [Gd@C82(OH)22]n nanoparticles in tumor-bearing mice
Wang, J., Chen, C., Li, B., Yu, H., Zhao, Y., Sun, J., Li, Y., Xing, G., Yuan, H., Tang, J., et al. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.12.001 · Cited by 160
Self-citationSafaei, R., Katano, K., Larson, B. J., Samimi, G., Holzer, A. K., Naerdemann, W., Tomioka, M., Goodman, M., & Howell, S. B. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.756.11.2 · Cited by 141
Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy
Basu, S., Harfouche, R., Soni, S., Chimote, G., Mashelkar, R. A., & Sengupta, S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902857106 · Cited by 129
Biopharmaceutics and Therapeutic Potential of Engineered Nanomaterials
Liang, X., Chen, C., Zhao, Y., Jia, L., & Wang, P. C. (2008) · Current Drug Metabolism · doi:10.2174/138920008786049230 · Cited by 119
Self-citationYin, J., Lao, F., Meng, J., Fu, P. P., Zhao, Y., Xing, G., Gao, X., Sun, B., Wang, P. C., Chen, C., et al. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.048348 · Cited by 119
Self-citationMcNeill, D. R., & Wilson, D. M. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0329 · Cited by 97
Liang, X., Shen, D., Garfield, S. H., & Gottesman, M. M. (2003) · PubMed · Cited by 95
Self-citationReduced endocytosis and altered lysosome function in cisplatin-resistant cell lines
Chauhan, S. S., Liang, X., Su, A. W., Panandiker, A. S. P., Shen, D. W., Hanover, J. A., & Gottesman, M. M. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600861 · Cited by 90
Self-citationKawai, K., Kamatani, N., Georges, E., & Ling, V. W. T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38277-8 · Cited by 85
Shen, D.-W., Akiyama, S.-I., Schoenlein, P. V., Pastan, I. H., & Gottesman, M. M. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.134 · Cited by 82
Self-citationMacFarland, D. K., Walker, K. L., Lenk, R. P., Wilson, S. R., Kumar, K., Kepley, C. L., & Garbow, J. R. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800521j · Cited by 69
Endocytic Recycling Compartments Altered in Cisplatin-Resistant Cancer Cells
Liang, X., Mukherjee, S., Shen, D., Maxfield, F. R., & Gottesman, M. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3436 · Cited by 60
Self-citationLiang, X., Shen, D., Chen, K. G., Wincovitch, S., Garfield, S. H., & Gottesman, M. M. (2004) · Journal of Cellular Physiology · doi:10.1002/jcp.20253 · Cited by 57
Self-citationShen, D.-W., Su, A., Liang, X.-J., Panandiker, A. S. P., & Gottesman, M. M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601956 · Cited by 49
Self-citationHMG-CoA Reductase Inhibitors in the Prevention of Stroke
Mil, A. H. M. V. D. H., Westendorp, R. G. J., Bollen, E. L. E. M., Lagaay, A. M., & Blauw, G. J. (2000) · Drugs · doi:10.2165/00003495-200059010-00001 · Cited by 32
Spalletti-Cernia, D., Sorrentino, R., Gaetano, S. D., Piccoli, R., Santoro, M. M., D’Alessio, G., Laccetti, P., & Vecchio, G. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601491 · Cited by 28
Shen, D., Liang, X., Gawinowicz, M. A., & Gottesman, M. M. (2004) · Molecular Pharmacology · doi:10.1124/mol.66.4.789 · Cited by 26
Self-citationDawidzik, J. B., Patrzyc, H. B., Iijima, H. K., Budzinski, E. E., Higbee, A. J., Cheng, H.-C., & Box, H. C. (2003) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(03)00071-0 · Cited by 14
Cited by
Carbon Nanomaterials for Biological Imaging and Nanomedicinal Therapy
Hong, G., Diao, S., Antaris, A. L., & Dai, H. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00008 · Cited by 1,394
Diverse Applications of Nanomedicine
Pelaz, B., Alexiou, C., Alvarez-Puebla, R. A., Alves, F., Andrews, A. M., Ashraf, S., Balogh, L. P., Ballerini, L., Bestetti, A., Brendel, C., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b06040 · Cited by 1,350
Self-citationPopov, A. A., Yang, S., & Dunsch, L. (2013) · Chemical Reviews · doi:10.1021/cr300297r · Cited by 1,256
Nanomaterials for Theranostics: Recent Advances and Future Challenges
Lim, E.-K., Kim, T., Paik, S., Haam, S., Huh, Y.-M., & Lee, K. (2015) · Chemical Reviews · doi:10.1021/cr300213b · Cited by 1,233
Cellular Uptake, Intracellular Trafficking, and Cytotoxicity of Nanomaterials
Zhao, F., Zhao, Y., Liu, Y., Chang, X., Chen, C., & Zhao, Y. (2011) · Small · doi:10.1002/smll.201100001 · Cited by 1,175
Self-citation
Metadata
- Authors
- Liang, X.-J., Meng, H., Wang, Y., He, H., Meng, J., Lu, J., Wang, P. C., Zhao, Y., Gao, X., Sun, B., Chen, C., Xing, G., Shen, D., Gottesman, M. M., Wu, Y., Yin, J.-J., & Jia, L.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2010-04-05
- Volume
- 107
- Issue
- 16
- Pages
- 7449-7454
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2036551119
- Cited by
- 256
- References
- 39
- FWCI
- 8.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.